Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Search

Research

COVID-19-Related Submission Priorities From the Journal of the Pediatric Infectious Diseases Society

Christopher Blyth CC MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases

Research

Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021

Antifungal agents can have complex dosing and the potential for drug interaction, both of which can lead to subtherapeutic antifungal drug concentrations and poorer clinical outcomes for patients with haematological malignancy and haemopoietic stem cell transplant recipients. Antifungal agents can also be associated with significant toxicities when drug concentrations are too high.

Research

Acute haemoptysis, fever and abdominal pain in an adolescent from northern Australia

Christopher Asha André Dr Anita Blyth Bowen Schultz Campbell CC AC AS AC MBBS (Hons) DCH FRACP FRCPA PhD BA MBBS DCH FRACP PhD GAICD OAM MBChB, PhD,

Research

Echinocandins in Pediatric Invasive Candidiasis and the Challenges of Antifungal Use in Children

In pediatric invasive candidiasis (IC), epidemiology and risk factors differ compared to adults. Furthermore, the use of antifungals in children is challenging and requires consideration of availability and tolerability of formulations, pharmacokinetic and pharmacodynamic variations, and safety in different age groups.

Research

COVID-19 and changes in the National Immunisation Program: a unique opportunity to optimise the Australian Immunisation Register (AIR)

Christopher Blyth CC MBBS (Hons) DCH FRACP FRCPA PhD Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases

Research

Vaccine coverage in children born to migrant mothers in Australia: A population-based cohort study

Overall, infant immunisation coverage is currently >90% in Australia, but there are pockets of under-immunised children including children from migrant backgrounds.

Research

Quality of benzathine penicillin G: A multinational cross-sectional study

Benzathine penicillin G (BPG) is used as first-line treatment for most forms of syphilis and as secondary prophylaxis against rheumatic heart disease (RHD). Perceptions that poor quality of BPG is linked to reported adverse effects and therapeutic failure may impact syphilis and RHD control programs. Clinical networks and web-based advertising were used to obtain vials of BPG from a wide range of countries.

Research

RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study

The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV). The level of its use and compliance with current jurisdictional guidelines which were amended in 2010, is unknown.

Research

Spotting sporotrichosis skin infection: The first Australian paediatric case series

These data highlight the importance of recognising Sporotrichosis in children outside an outbreak setting

Research

The impact of new universal child influenza programs in Australia: Vaccine coverage, effectiveness and disease epidemiology in hospitalised children in 2018

A significant reduction in severe influenza was observed in Australian children, possibly contributed to by improved vaccine coverage and high vaccine effectiveness